SCHEMBL10132281

SCHEMBL10132281

CCN1CCN(c2ccc(C)cc2)C(C)C1

nearest known ligand 0.51

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
MAPK1 P28482 1/20 0.51
ALDH1A1 P00352 2/20 0.46
MAPT P10636 6/20 0.43
LMNA P02545 3/20 0.43
GFER P55789 1/20 0.43
POLB P06746 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.41
NPSR1 Q6W5P4 1/20 0.41
TDP1 Q9NUW8 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
MEN1 O00255 1/20 0.41
KMT2A Q03164 1/20 0.41
TP53 P04637 1/20 0.40
DRD2 P14416 1/20 0.40
DRD4 P21917 1/20 0.40
TSHR P16473 1/20 0.39
HTT P42858 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18948460 0.85 MAPK1 (0.50) MAPK1MAPTGFERSMN1; SMN2DRD2
SCHEMBL15859012 0.85 MAPK1 (0.50) MAPK1MAPTGFERSMN1; SMN2DRD2
SCHEMBL16549649 0.85 MAPK1 (0.69) MAPK1MAPTTP53DRD2DRD4
SCHEMBL12126936 0.83 KDM4E (0.52) MAPK1ALDH1A1MAPTLMNASMN1; SMN2
SCHEMBL15787899 0.83 MAPK1 (0.48) MAPK1ALDH1A1MAPTLMNAGFER
SCHEMBL10161179 0.81 MAPK1 (0.47) MAPK1DRD2DRD4
SCHEMBL12126930 0.81 MAPT (0.61) MAPK1ALDH1A1MAPTLMNAGFER
SCHEMBL23316353 0.79 RAD52 (0.61) MAPK1ALDH1A1MAPTLMNAGFER
SCHEMBL27363818 0.78 MAPK1 (0.47) MAPK1MAPTLMNAGFERPOLB
SCHEMBL2610122 0.77 SMN1; SMN2 (0.47) MAPK1ALDH1A1MAPTLMNAGFER

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8957075-B2 O-GlcNAc transferase inhibitors and uses thereof PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2015-02-17 US disclosed
US-20120108605-A1 O-GLCNAC TRANSFERASE INHIBITORS AND USES THEREOF PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2012-05-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120108605-A1 O-GLCNAC TRANSFERASE INHIBITORS AND USES THEREOF OGA, OGT, UGGT1 MAPK1 2740/4885ALDH1A1 1153/4885MAPT 759/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.